Venture Capital Still Flowing to Life Sciences, Stoking Innovation

Jan. 26, 2017, 7:07 PM

Companies chasing products in precision medicine and digital health are getting more venture capital love as investors see the upside of innovations in genomics and other cutting-edge technologies.

Life sciences deals with valuations exceeding $100 million doubled to 28 percent in the third quarter from 14 percent in the first quarter of 2016. That compares to technology deals with similar valuations dropping to 23 percent from 29 percent during the same period, the Cooley Venture Financing Report for the third quarter said.

Amid declining U.S. venture capital deal activity, health-care companies attracted $11 billion in venture funding...

To read the full article log in.

Learn more about A Bloomberg Law subscription.